Monte Competitors
| GLUE Stock | USD 20.93 0.05 0.24% |
Monte Rosa vs MeiraGTx Holdings Correlation
Excellent diversification
The correlation between Monte Rosa Therapeutics and MGTX is -0.52 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Monte Rosa Therapeutics and MGTX in the same portfolio, assuming nothing else is changed.
Moving together with Monte Stock
Moving against Monte Stock
| 0.84 | GNLX | Genelux Common | PairCorr |
| 0.79 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.76 | LYRA | Lyra Therapeutics | PairCorr |
| 0.72 | ABP | Abpro Holdings | PairCorr |
| 0.69 | EDIT | Editas Medicine | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Monte Rosa's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Monte Rosa Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Monte Rosa and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Monte and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Monte Rosa Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Monte Stock performing well and Monte Rosa Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Monte Rosa's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | 4.35 | 0.87 | 0.21 | 1.53 | 3.61 | 13.81 | 39.62 | |||
| ARVN | 3.06 | 0.60 | 0.16 | 2.94 | 3.12 | 5.91 | 28.90 | |||
| REPL | 2.58 | (0.47) | 0.00 | (0.78) | 0.00 | 5.56 | 14.00 | |||
| TBPH | 2.23 | 0.54 | 0.21 | 0.71 | 2.14 | 3.82 | 28.70 | |||
| AVBP | 2.96 | 0.32 | 0.10 | 0.47 | 3.00 | 6.71 | 18.12 | |||
| GERN | 2.81 | 0.27 | 0.10 | 0.16 | 2.84 | 7.76 | 16.99 | |||
| VIR | 3.34 | 0.41 | 0.11 | 0.27 | 3.40 | 8.08 | 20.46 | |||
| DNA | 3.35 | (0.39) | 0.00 | 1.98 | 0.00 | 8.16 | 28.96 | |||
| VALN | 2.20 | 0.03 | 0.00 | 0.57 | 2.35 | 4.83 | 15.59 | |||
| MGTX | 2.52 | (0.19) | 0.00 | (0.07) | 0.00 | 5.08 | 14.00 |
Cross Equities Net Income Analysis
Compare Monte Rosa Therapeutics and related stocks such as Day One Biopharmaceu, Arvinas, and Replimune Group Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (95.5 M) | (85.9 M) | (90.2 M) |
| ARVN | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (24 M) | (41.5 M) | (62.1 M) | (111.8 M) | (183.2 M) | (271.9 M) | (367.3 M) | (198.9 M) | (179 M) | (188 M) |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (174.3 M) | (215.8 M) | (247.3 M) | (222.6 M) | (211.4 M) |
| TBPH | (109.3 M) | (109.3 M) | (9.6 M) | (156.3 M) | (237 M) | (182.2 M) | (190.7 M) | (285.4 M) | (215.5 M) | (236.5 M) | (278 M) | (199.4 M) | 872.1 M | (55.2 M) | (56.4 M) | (64.9 M) | (68.1 M) |
| AVBP | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (36.9 M) | (69.3 M) | (80.5 M) | (80.5 M) | (72.4 M) | (76.1 M) |
| GERN | (10.7 M) | (96.9 M) | (68.9 M) | (38.4 M) | (35.7 M) | 46 K | (29.5 M) | (27.9 M) | (27 M) | (63.6 M) | (75.6 M) | (116.1 M) | (141.9 M) | (184.1 M) | (174.6 M) | (157.1 M) | (149.3 M) |
| VIR | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (115.9 M) | (174.7 M) | (298.7 M) | 528.6 M | 515.8 M | (615.1 M) | (522 M) | (469.8 M) | (446.3 M) |
| DNA | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (126.6 M) | (1.8 B) | (2.1 B) | (892.9 M) | (547 M) | (492.3 M) | (516.9 M) |
| VALN | (1.2 M) | (4.4 M) | (14.8 M) | (24.1 M) | (26.3 M) | (20.6 M) | (49.2 M) | (11.5 M) | 3.3 M | (1.7 M) | (64.4 M) | (73.4 M) | (143.3 M) | (101.4 M) | (12.2 M) | (11 M) | (11.6 M) |
| MGTX | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (31 M) | (82.9 M) | (54.7 M) | (58 M) | (79.6 M) | (129.6 M) | (84 M) | (147.8 M) | (133 M) | (126.4 M) |
Monte Rosa Therapeutics and related stocks such as Day One Biopharmaceu, Arvinas, and Replimune Group Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Monte Rosa Therapeutics financial statement analysis. It represents the amount of money remaining after all of Monte Rosa Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Monte Rosa Competitive Analysis
The better you understand Monte Rosa competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Monte Rosa's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Monte Rosa's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Monte Rosa Competition Performance Charts
Five steps to successful analysis of Monte Rosa Competition
Monte Rosa's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Monte Rosa Therapeutics in relation to its competition. Monte Rosa's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Monte Rosa in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Monte Rosa's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Monte Rosa Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Monte Rosa position
In addition to having Monte Rosa in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Agency Mbs ETFs Thematic Idea Now
Agency Mbs ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Agency Mbs ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agency Mbs ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Monte Rosa Correlation with its peers. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Biotechnology sector continue expanding? Could Monte diversify its offerings? Factors like these will boost the valuation of Monte Rosa. Market participants price Monte higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Monte Rosa data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.32 | Revenue Per Share | Quarterly Revenue Growth 0.385 | Return On Assets | Return On Equity |
Monte Rosa Therapeutics's market price often diverges from its book value, the accounting figure shown on Monte's balance sheet. Smart investors calculate Monte Rosa's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Monte Rosa's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.